 |
0 Diseases |  |
2 Trials |
|
2 Trials |  |
198 News |  |
| «123 |
- | Keytruda (pembrolizumab) / Merck (MSD), Cavatak (gebasaxturev) / Merck (MSD)
New P1/2 trial, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: Pembrolizumab + CVA21 in Advanced NSCLC (clinicaltrials.gov) - Jul 7, 2016
P1/2, N=40, Not yet recruiting, Sponsor: Olivia Newton-John Cancer Research Institute
- Cavatak (gebasaxturev) / Merck (MSD)
Enrollment closed, Enrollment change: CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON) (clinicaltrials.gov) - May 26, 2016
P1, N=15, Active, not recruiting, Sponsor: Viralytics
Recruiting --> Active, not recruiting | N=33 --> 15
- | Cavatak (gebasaxturev) / Merck (MSD)
Trial completion, Enrollment change, Trial primary completion date, Metastases: CALMext: CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext) (clinicaltrials.gov) - Apr 16, 2016
P2, N=16, Completed, Sponsor: Viralytics
Recruiting --> Active, not recruiting | N=33 --> 15 Active, not recruiting --> Completed | N=67 --> 16 | Trial primary completion date: Jan 2016 --> Apr 2016
- || Keytruda (pembrolizumab) / Merck (MSD), Cavatak (gebasaxturev) / Merck (MSD)
Enrollment change, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker: CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200) (clinicaltrials.gov) - Apr 14, 2016
P1, N=90, Recruiting, Sponsor: Viralytics
Active, not recruiting --> Completed | N=67 --> 16 | Trial primary completion date: Jan 2016 --> Apr 2016 N=33 --> 90 | Trial primary completion date: Dec 2016 --> Aug 2019
- Keytruda (pembrolizumab) / Merck (MSD), Cavatak (gebasaxturev) / Merck (MSD)
Enrollment change, Metastases: Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA) (clinicaltrials.gov) - Oct 30, 2015
P1, N=30, Recruiting, Sponsor: Viralytics
N=33 --> 90 | Trial primary completion date: Dec 2016 --> Aug 2019 N=45 --> 30
- Keytruda (pembrolizumab) / Merck (MSD), Cavatak (gebasaxturev) / Merck (MSD)
Enrollment open, Metastases: Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA) (clinicaltrials.gov) - Oct 30, 2015
P1, N=30, Recruiting, Sponsor: Viralytics
N=45 --> 30 Not yet recruiting --> Recruiting
- | Keytruda (pembrolizumab) / Merck (MSD), Cavatak (gebasaxturev) / Merck (MSD)
New P1 trial, Metastases: Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA) (clinicaltrials.gov) - Oct 1, 2015
P1, N=30, Not yet recruiting, Sponsor: Viralytics
- ||| Cavatak (gebasaxturev) / Merck (MSD)
Enrollment closed, Metastases: CALMext: CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext) (clinicaltrials.gov) - Aug 12, 2015
P2, N=67, Active, not recruiting, Sponsor: Viralytics
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Cavatak (gebasaxturev) / Merck (MSD)
Trial primary completion date, Metastases: CALMext: CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext) (clinicaltrials.gov) - Jun 11, 2015
P2, N=67, Recruiting, Sponsor: Viralytics
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2015 --> Jan 2016
- |||| Cavatak (gebasaxturev) / Merck (MSD)
Trial completion, Trial primary completion date, Metastases: A Study of Intratumoral CAVATAK (clinicaltrials.gov) - Jun 11, 2015
P2, N=57, Completed, Sponsor: Viralytics
Trial primary completion date: Jan 2015 --> Jan 2016 Trial primary completion date: Jan 2014 --> Jun 2015 | Recruiting --> Completed
- Cavatak (gebasaxturev) / Merck (MSD)
Enrollment open, Metastases: Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI) (clinicaltrials.gov) - Feb 26, 2015
P1, N=26, Recruiting, Sponsor: Viralytics
Trial primary completion date: Jan 2014 --> Jun 2015 | Recruiting --> Completed Not yet recruiting --> Recruiting
- Cavatak (gebasaxturev) / Merck (MSD)
Enrollment open: CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON) (clinicaltrials.gov) - Jan 11, 2015
P1, N=33, Recruiting, Sponsor: Viralytics
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Cavatak (gebasaxturev) / Merck (MSD)
New P1 trial: CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON) (clinicaltrials.gov) - Dec 13, 2014
P1, N=33, Not yet recruiting, Sponsor: Viralytics
- | Cavatak (gebasaxturev) / Merck (MSD)
New P1 trial, Metastases: Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI) (clinicaltrials.gov) - Dec 7, 2014
P1, N=26, Not yet recruiting, Sponsor: Viralytics
- ||| Cavatak (gebasaxturev) / Merck (MSD)
Enrollment change, Metastases: A Study of Intratumoral CAVATAK (clinicaltrials.gov) - Jul 4, 2014
P2, N=69, Recruiting, Sponsor: Viralytics
Not yet recruiting --> Recruiting N=57 --> 69
- |||| Cavatak (gebasaxturev) / Merck (MSD)
Enrollment open, Enrollment change, Metastases: A Study of Intratumoral CAVATAK (clinicaltrials.gov) - Jul 4, 2014
P2, N=69, Recruiting, Sponsor: Viralytics
N=57 --> 69 Completed --> Recruiting | N=57 --> 69
- Keytruda (pembrolizumab) / Merck (MSD), Cavatak (gebasaxturev) / Merck (MSD)
Enrollment open, Combination therapy, PD(L)-1 Biomarker: CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200) (clinicaltrials.gov) - Mar 1, 2014
P1, N=33, Recruiting, Sponsor: Viralytics
Completed --> Recruiting | N=57 --> 69 Not yet recruiting --> Recruiting
- | Keytruda (pembrolizumab) / Merck (MSD), Cavatak (gebasaxturev) / Merck (MSD)
New P1 trial, Combination therapy, PD(L)-1 Biomarker: CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200) (clinicaltrials.gov) - Jan 21, 2014
P1, N=33, Recruiting, Sponsor: Viralytics
- |||| Cavatak (gebasaxturev) / Merck (MSD)
Trial completion, Metastases: A Study of Intratumoral CAVATAK (clinicaltrials.gov) - Jan 19, 2014
P2, N=57, Completed, Sponsor: Viralytics
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||||| Cavatak (gebasaxturev) / Merck (MSD)
New P2 trial, Metastases: CALMext: CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext) (clinicaltrials.gov) - Jul 8, 2012
P2, N=67, Recruiting, Sponsor: Viralytics
- Cavatak (gebasaxturev) / Merck (MSD)
Trial completion, Metastases: Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04) (clinicaltrials.gov) - Jun 6, 2012
P1, N=8, Completed, Sponsor: Viralytics
Recruiting --> Completed Terminated --> Completed
- Cavatak (gebasaxturev) / Merck (MSD)
Trial termination: A Study of the Intratumoural Administration of CAVATAK to Head and Neck Cancer Patients (VLA-X06) (clinicaltrials.gov) - Feb 21, 2012
P1, N=4, Terminated, Sponsor: Viralytics
Terminated --> Completed Recruiting --> Terminated; Poor recruitment rate.